DAMATO, Valentina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.433
EU - Europa 1.084
AS - Asia 347
AF - Africa 22
SA - Sud America 3
Totale 2.889
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.430
RU - Federazione Russa 648
IE - Irlanda 167
IT - Italia 167
SG - Singapore 151
HK - Hong Kong 88
CN - Cina 54
IN - India 43
SE - Svezia 40
GB - Regno Unito 26
CI - Costa d'Avorio 20
FI - Finlandia 12
UA - Ucraina 10
NL - Olanda 6
FR - Francia 5
IR - Iran 4
CA - Canada 3
CL - Cile 2
JP - Giappone 2
MA - Marocco 2
SA - Arabia Saudita 2
AT - Austria 1
BR - Brasile 1
CH - Svizzera 1
DE - Germania 1
JO - Giordania 1
KR - Corea 1
KZ - Kazakistan 1
Totale 2.889
Salva come PNG Salva come JPEG
Città #
Santa Clara 754
Dublin 165
Singapore 134
Altamura 80
Lawrence 80
Kent 63
Fairfield 47
Hong Kong 47
Boston 41
Princeton 41
Moscow 39
Ashburn 35
Mumbai 31
Abidjan 20
San Diego 17
Wilmington 17
Rome 15
Shanghai 15
Seattle 12
West Jordan 12
Hillsboro 10
Woodbridge 10
Florence 9
London 9
Helsinki 8
Medford 8
Pune 8
Yubileyny 8
Cambridge 7
Milan 7
Andover 6
Beijing 6
Genoa 6
Houston 4
Lappeenranta 4
Ann Arbor 3
Chicago 3
Kilburn 3
Naples 3
Toronto 3
Boca Raton 2
Chennai 2
Cincinnati 2
Dammam 2
Delhi 2
Epsom 2
Gualtieri 2
Guangzhou 2
Legnaro 2
Nakanoki 2
New York 2
Perugia 2
Pescara 2
Pontivy 2
Prescot 2
Salé 2
Shiraz 2
Trieste 2
Trino 2
Vernon Hills 2
Aci Sant'Antonio 1
Almaty 1
Bari 1
Bern 1
Boulder 1
Bromley 1
Carugate 1
Davis 1
Fontebuona 1
Harringay 1
Hollywood 1
Hounslow 1
Jiaxing 1
Jinhua 1
Jiujiang 1
Latina 1
Los Angeles 1
New Bedfont 1
Newark 1
Paris 1
Partinico 1
Romola 1
Santiago 1
Seoul 1
Sesto Fiorentino 1
Shenyang 1
Shenzhen 1
Slough 1
St Louis 1
São Paulo 1
Vienna 1
Wuhan 1
Zhenjiang 1
Totale 1.863
Salva come PNG Salva come JPEG
Nome #
Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis 69
Consistent improvement with eculizumab across muscle groups in myasthenia gravis 65
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: A case series of 22 patients 61
Conventional and emerging treatments and controversies in myasthenia gravis 59
Creutzfeldt-Jakob disease manifesting as stroke mimic in a 78-year-old patient: Pitfalls and tips in the diagnosis 59
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 58
Diagnostic algorithms in autoimmune encephalitis 58
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 58
Benefit and danger from immunotherapy in myasthenia gravis 58
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic aetiology 57
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 56
Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma 56
3,4-Diaminopyridine may improve myasthenia gravis with M u SK antibodies 56
Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis 55
Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis 55
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update 55
Long-term-video monitoring EEG and 18F-FDG-PET are useful tools to detect residual disease activity in anti-LGI1-Abs encephalitis: A case report 53
Anorexia heralding the onset of neuromyelitis optica 53
Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis 52
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 52
Type 1 immune response in progressive multiple sclerosis 52
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 50
Myasthenia gravis and related disorders 50
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis 50
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 50
Heterogeneity in myasthenia gravis: considerations for disease management 50
Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis 49
Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders 49
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 49
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 49
Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors 48
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 48
Response to: “MuSK-positive myasthenia may be triggered not only by SARS-CoV-2” 47
Serological and experimental studies in different forms of myasthenia gravis 47
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 47
In reply 47
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 47
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study 47
Eculizumab improves fatigue in refractory generalized myasthenia gravis 47
Distinct lymphocytes subsets in IgM-related neuropathy: clinical-immunological correlations 47
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 46
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 46
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 46
Myasthenia gravis with antibodies to MuSK: An update 46
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 46
‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab 46
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 45
When myasthenia gravis is not all 44
Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection 43
Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4 43
Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet 42
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 41
The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders 41
Clinical, neurophysiological and serological clues for the diagnosis of neuromyotonia and distinction from cramp-fasciculation syndrome 40
Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders 39
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room 34
Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with Rituximab 33
Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors 29
Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis 25
Teaching Video NeuroImage: The “Chameleon Eyes Sign” in Myasthenia Gravis 24
Epidemiology of seropositive myasthenia gravis in Sardinia: A population‐based study in the district of Sassari 23
Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia 23
Thymic hyperplasia after autologous hematopoietic stem cell transplantation in multiple sclerosis: a case series 3
Totale 2.963
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.454
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.454
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 0 0 0 0 0 0 104 24 1 14 75
2022/2023491 68 161 16 17 0 89 89 3 19 10 13 6
2023/2024402 11 17 68 17 33 40 15 63 9 35 72 22
2024/20251.852 94 316 158 395 889 0 0 0 0 0 0 0
Totale 2.963